Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-06-19
2007-06-19
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S363000, C544S048000, C544S049000, C544S105000, C544S235000, C544S236000, C544S237000, C544S353000
Reexamination Certificate
active
10674098
ABSTRACT:
The present invention provides compounds of Formula I or II that are useful as anti-cancer agents and other diseases that can be treated by inhibiting tyrosine kinase enzymes
REFERENCES:
patent: 6479512 (2002-11-01), Fraley et al.
patent: 6605617 (2003-08-01), Renhowe et al.
patent: 2002/0103230 (2002-08-01), Renhowe et al.
patent: 2002/0107392 (2002-08-01), Renhowe et al.
patent: 2003/0028018 (2003-02-01), Renhowe et al.
patent: 2005/0256157 (2005-11-01), Gesner et al.
patent: 2005/0261307 (2005-11-01), Cai et al.
patent: 63-230687 (1988-09-01), None
patent: 11321093 (1999-11-01), None
patent: WO 02/22598 (2002-03-01), None
patent: WO 2004/018419 (2004-03-01), None
Katzung et al. Basic and Clinical Pharmacology. Seventh Edition. Appleton& Lange. 1998. pp. 882-884.
Emerging approaches to antiangiogenic therapies for treating cancer, posted Nov. 3, 2005 on http://www.nyas.org/ebriefreps/main.asp?intSubsectionID=3099.
Burke Stem Cells, vol. 12, pp. 1-6 (1994).
Brower Nature Biotech. vol. 17, pp. 963-968 (1999).
Carmeliet et al. Nature, vol. 407, pp. 249-257 (2000).
Hennequin et al. J.Med. Chem. vol. 42, pp. 5369-5389 (1999).
Vippagunta et al. Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Pending U.S. Appl. No. 60/490,889, filed Jul. 29, 2003.
Pending U.S. Appl. No. 10/263,448, filed Oct. 2, 2002.
Pending U.S. Appl. No. 10/751,798, filed Jan. 5, 2004.
Velaparthi Upender
Wittman Mark D.
Bernhardt Emily
Bristol--Myers Squibb Company
Gibbons Maureen S.
Korsen Elliot
LandOfFree
Tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tyrosine kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3875982